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Management of localized and advanced prostate cancer benefits from several
therapeutic options with a surprising improvement in terms of clinical outcome. The
selection of patients more likely to benefit from a specific approach still remains a key
issue as well as the early identification of patients with aggressive disease which could
benefit from a more aggressive treatment strategy. The lack of reliable bio-marker in
castration resistant setting able to monitor response to treatment and early inform about
tumor progression is an emerging issue. Accordingly, circulating DNA and circulating
tumor cells appears a promising and attractive approach despite to date practical
applications of these techniques are few and not validated. The aim of this review of
the literature is to explore current knowledge on liquid biopsy in prostate cancer focusing
on possible future applications.
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INTRODUCTION
Prostate Cancer (PCa) represents the most common adult malignancies ranking as one of the
major cause of cancer related death in men (1). Management of the disease accounts various
options in both localized and advanced stages. Each options are generally evaluated according to
different variables related to patients (performance status, comorbidities, disease related symptoms,
and patients’ preferences) and tumor features (biological aggressiveness and site and number of
metastases). Thus, the management of localized stages could range from a first instance no invasive
approach (watchful waiting or active surveillance approach) to a radical approach by surgery,
external radiation treatment, a combination of both of them (radiation treatment in case of positive
surgical margins) or also brachytherapy (which consists on the prostate implantation of sealed
radiotherapy sources) with or without an adjuvant androgen deprivation therapy (ADT) (2–8).
Similarly, advanced stages of the disease count different therapeutic options. As first approach
ADT represents the cornerstone of advanced prostate cancer due to the high sensitivity of
tumor cells to hormone deprivation. The addiction of further treatment including anti-androgens
abiraterone acetate or docetaxel can improve the outcome of patients with metastatic castration
sensitive prostate cancer (mCSPC) (9–15).
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After a first period of hormone deprivation sensitivity, tumor
cells develop several mechanisms which lead to overcome the
hormone inhibition leading to metastatic castration resistant
prostate cancer (mCRPC). In this setting, several different agents
have demonstrated to be effective treatment: new hormonal
agents (abiraterone, enzalutamide, apalutamide), chemotherapy
(docetaxel, cabazitaxel), radiometabolic drugs (Radium 223), and
Sipuleucel-T immunotherapy (16–25).
RATIONAL FOR LIQUID BIOPSY IN
PROSTATE CANCER
The availability of several active therapeutic options has led
to different emerging needs in clinical practice requiring the
development of reliable markers able to monitor response to
treatment and help clinicians to select patients more likely to
benefit from one approach rather than another.
Prostate-Specific Antigen (PSA) represents a reliable and
useful biomarker adopted for early detection and early diagnosis
of disease recurrence progression. However, it does not give
information about biological features of the disease and it loses
its predictive rule in mCRPC setting (26).
Liquid biopsy is an emerging technique which purposes is the
detection of tumor cells/tumor DNA from patients’ peripheral
blood.
There are several issues whichmake the development of liquid
biopsies in prostate cancer an attractive approach: (1) the low
invasiveness; (2) the early detection of more aggressive tumors
since early phases;(3) the early diagnosis of residual tumors or
micro-metastases after surgery. (4) the monitoring of tumor
response/progression to systemic treatment in advanced setting
of the disease and especially in mCRPC; (5) the prediction
of tumor sensitivity/resistance to systemic treatments; (6) the
acquisition of an accurate genetic assessment of the disease
focusing on key alterations which are related to tumor resistance.
In particular, several genomic alterations seem to be attractive
target due to their correlation to treatment resistance and/or
sensitivity to specific treatments (27–30). Some of the more
attractive targets are:
- Phosphate and tensin homolog (PTEN) loss. PTEN loss
results in PI3K/AKT activation which has been associated
to worst survival due to higher tumor proliferation and
resistance to hormonal treatment. The inhibition of the
PI3K/AKT/mTOR pathway could be an interesting target in
this subgroup of patients which could be associated to an
Androgen Receptor (AR) inhibition (31, 32).
- MYC amplification is generally acquired in metastatic phases
of the disease and is correlated to poor prognosis and higher
Gleason score. Furthermore, more than one evidences seem
to correlate the combination of MYC amplification and PTEN
loos to worst prognosis and increase risk of tumor related
death (33, 34).
- Androgen Receptor (AR) mutations and in particular AR
splice variant 7 (AR-V7) is known to be related to resistance
to hormonal treatments including also new hormonal agents
abiraterone and enzalutamide (35).
- TMPRSS2-ERG gene fusion leads to ETS-related gene (ERG)
and steroidogenic enzyme AKR1C3 co-overexpression which
promotes AR signaling and represents a promising target in
prostate cancer (36, 37).
- DNA repair genes deficiency and in particular genes
related to the identification of single strand breaks (such
as PARP1 and PARP2) as well as the identification of the
alterations of non-homologous recombination system genes
(such as BRCA1, BRCA2, PALBB2, MRE11, Check2, RAD51,
XRCC2/3) appears an attractive approach for two reason.
First, tumors with repair genes deficiency are related to more
aggressive features and poorer survival. Second, therapeutic
implications related to these genomic assessments involve
a possible sensitivity to platinum cytotoxic therapy. The
development of PARP inhibitors represents another possible
target for the management of advanced prostate cancer which
has already been evaluated in small trials and is currently
under clinical investigation (38–43).
Due to these issues, the development of reliable techniques
able to perform liquid biopsy appears a promising and suggestive
approach (Table 1). Here we performed a review of the main
techniques adopted or under investigation focusing our attention
on approaches based on circulating tumor cell (CTC) and
circulating DNA (ct-DNA) detection. Table 2 summarizes the
current methods available for CTC detection as well as the
percentage of detection (See also below).
CIRCULATING TUMOR CELLS IN
PROSTATE CANCER
To date, the CellSearch system assay is the only FDA approved
method for the detection of CTCs in prostate cancer (Table 2).
This device consists of different components including a CellPrep
system which is a semi-automated sample preparation system
and a CellSearch Epithelial Cell Kit. This last component involves
ferro-fluids coated with epithelial cell-specific EpCAMantibodies
and a mixture of antibodies directed against cytokeratins 8, 18,
19, CD45 conjugated to allophycocyanin and DAPI (nuclear
dye 4’, 6 diamidino-2-phenylindole for fluorescent cells label).
After an incubation period in which CTC are isolated from
peripheral blood and enriched in EpCAM composed ferro-fluids
the MagNest Cell Presentation Device (a device composed of a
chamber with two magnets) orients labeled cells for analysis in a
CellSpotter Analyzer (a four-color semi-automated fluorescence
microscope) for the CTCs enumeration (44).
Initial studies carried out on patients with different solid
tumor demonstrated a promising activity with this method and
regarding patients with PCa detection of CTCs was possible in
57% of patients (44).
Further study aimed to investigate the clinical value of CTCs
detected by CellSearch assay showed that CTCs baseline levels
were an independent prognostic factor for overall survival (OS)
(49).
In 2008, de Bono et al. identified a correlation between CTCs
number and median overall survival. In this study carried out
on 231mCRPC two distinct subgroup of patients were identified:
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TABLE 1 | An overview of ongoing clinical studies evaluating CTCs/ctDNA in prostate cancer patients.
Trial Patients enrolled Study description/outcomes
NCT03284684 Patients undergoing surgery for non-metastatic
solid tumors: colon, breast and prostate.
Change in concentration of total mutant circulating DNA. Change in proportion of
mutant circulating DNA. Change in integrity index of circulating DNA for ACTB gene.
Change in integrity index of circulating DNA for KRAS gene.
NCT02449837 Patients undergoing radiation treatments for
one of six cancer types including PC.
To measure CTCs levels to evaluate the change pre- and post-treatment. Change in
CTC levels from Baseline to Post-RT treatment and the correlation with local tumor
response or pathological evaluation
NCT01961713 Subjects with prostate cancer diagnosed on
prostate biopsy who undergo radical
prostatectomy
To evaluate the relationship between pre-operative CTC quantity and pathologic
stage in men with early stage prostate cancer undergoing prostatectomy.
To examine the relationship between persistent CTCs and biochemical recurrence
after radical prostatectomy for localized prostate cancer
NCT02997709 Men with intermediate to high risk prostate
cancer who are candidates for radiotherapy
(RT)
Comparison of Pre- and Post-Treatment Quantitative Imaging Parameters to Changes
in Circulating Tumor Cells Over Time in Prostate Cancer Patients Receiving Radiation
Therapy (RT) with or without Androgen Deprivation Therapy per standard of care
NCT02853097 Prostate cancer patients at various points
throughout androgen deprivation therapy and
at the initiation of androgen deprivation therapy,
enzalutamide, abiraterone and docetaxel.
To document the appearance of androgen receptor isoform splice variant 7 (AR-V7)
expression over the course of therapy in castration-resistant prostate cancer (CRPC).
To determine whether detectable AR-V7 is associated with a shortened duration of
treatment benefit of abiraterone or enzalutamide.
NCT03089099 mCRPC To determine whether sequentially analyzing the expression of molecular markers in
high volume circulating tumor cells in metastatic castration-resistant prostate cancer
patients can predict the therapeutic effects and outcomes of these patients.
NCT03488706 Prostate cancer screening with PSA is plagued
by high rate of unnecessary prostate biopsies,
especially in the “gray zone” (PSA levels:
4.00 ng/ml e 10.99 ng/ml)
Circulating tumor cells detection
Using a circulating-tumor-cell (CTC) test to detect prostate cancer in patients in the
PSA “gray zone” level
NCT03236688 mCRPC Demonstrate detection of ARv7 splice variant transcripts from exosomes in the
circulation of MCRPC patients pre and post treatment with selective Androgen
pathway inhibitors (i.e., abiraterone and enzalutamide)
NCT02771769 Patients with planned prostate biopsy Multi-center prospective study in which blood samples will be taken from 1500 male
patients aged between 21–80 scheduled for prostate biopsy. Analysis of cell-free
cancer DNA extracted from these samples will be undertaken to determine whether
copy number instability scores derived from the cfDNA correlates with PSA screening
levels and prostate biopsy results (i.e., Gleason score) in these patients
NCT02723526 Patients with newly Diagnosed Metastatic
Hormone-Sensitive Prostate Cancer
To determine whether sequentially analyzing the expression of tumor markers in
circulating tumor cells in newly diagnosed metastatic hormone-sensitive prostate
cancer patients can predict the outcome of these patients.
NCT02742259 Metastatic prostate cancer to the bone Confirmation of the clinical utility of the cutoff level for the Prostate Cancer Assay for
prognosis of progression free survival (PFS) in comparison to the predicate device,
CellSearch CTC Assay
NCT02456571 Metastatic PC To explore the prevalence of expression of four immune checkpoint biomarkers on
circulating tumor cells (CTCs) from men with metastatic prostate cancer
NCT02735252 Metastatic PCa. Develop a first-in-man CTC-based molecular taxonomy of CRPC. Comparison of
median PFS to CTC-based AR-v7 status.
NCT02099864 Advanced PCa patients receiv- ing
enzalutamide therapy.
Correlation between PSA response and gene expression signatures, DNA copy
number alterations, mutations. Assess the association for changes in CTC counts
from baseline and maximal PSA observed while on study.
one (Unfavorable group) which showed a CTCs number of 5
or more and the other (favorable) with < 5 CTCs per 7.5mL
of blood. Overall survival was significantly better in favorable
group (21.7 vs. 11.5 months). Moreover, patients who presented
a significant decrease of CTCs number during or after treatment
(moving from unfavorable to favorable groups) significantly
improved their survival compared to patients who continued
to present a CTCs number of 5 or more CTCs. According
to the results of de Bono et al, a meta-analysis of 10 studies
confirmed the prognostic rule of CTCs in patients with prostate
cancer (50).
Furthermore, pre-planned analyses of large phase III trials:
SWOG 20421 (docetaxel with or without atrasentain in
mCRPC patients), COU-AA-301 (in which a score composed
by LDH levels and CTCs divided patients in 3 different
subgroups with favorable, intermediate and poor prognosis) and
AFFIRM (enzalutamide in patients with mCRPC progressed
to chemotherapy) confirmed the prognostic rule of CTCs as
independent factor related to OS (51–53).
Unfortunately, none of these studies demonstrated an
association between CTCs number and response to treatment
and so the role of CTCs in this setting still remains unclear.
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TABLE 2 | An overview of CTCs detection techniques.
Method Mechanism CTCs detection rate/
other outcomes
Limitations
CELLSEARCH
System (44)
A 7.5mL sample of blood is placed in a special tube, centrifuged to separate solid
blood components from plasma, then placed in the CELLTRACKS® AUTOPREP®
System. Cells binds ferro-fluid nanoparticles presenting antibodies targeting epithelial
adhesion molecules, then CTCs are magnetically separated from other blood cells.
CTCs are stained with cytokeratin monoclonal antibodies, DAPI (a DNA stain) and
leukocytes which may have contaminated the sample are marked by antibody
targeting CD45. Stained CTCs are then placed onto Cell-Spotter Analyzer (a
four-color semi-automated fluorescence microscope) for the CTCs enumeration
CTCs+:
DAPI+, cytokeratine +, CD45—cells
CTCs detected in 57% of
patients with prostate
cancer
- Low CTCs detection rate in
non-metastatic prostate cancer
- Conflicting results about
correlation between CTCs
number and treatment
response.
CELLCOLLECTOR
EPISPOT (45)
Cell-Collector is based on a sterile stainless steel medical wire, covered with 2µm
gold and a hydrogel layer which is covalently coupled with antibodies against the
EpCAM protein and pan-keratins. CD45 staining (performed to exclude unspecific
leucocytes)
CTCs +:
CTCs identified as pan-keratin positive, leukocyte marker CD45 negative.
EPISPOT on an EpCAM-independent enrichment method (i.e., leukocyte depletion)
and enables the identification of viable PSA-secreting tumor cells
CTCs+:
PSA+ cells.
Combining Cellsearch,
CellCollector and Epispot
assay, detection rate of
CTCs was 81.3%
- Experimental approach.
- This approach does not offer a
characterization of CTCs.
- Impact on prognosis and
predictive value under
investigation.
Microfluidic
capture of CTCs
(46).
Considering the expression of PSA (up-regulated by AR) and PSMA (down regulated
by AR) they classified CTCs in AR on, AR mixed and AR positive according to the
expression of PSA (+ in AR on and mixed) and PSMA (+ in AR off and mixed).
CTCs detection rate: 80% - Experimental approach
- Under investigation for
detection of anti-androgen
resistance mechanisms.
EPCAM cells
enrichment and
sequencing (47).
The recovered cells, enriched with CTCs, were deposited into dense arrays of
subnanoliter wells and imaged by automated epifluorescence imaging. Enrichment
was obtained through Illumina MagSweeper CTCs expressing EpCAM. Individual
EpCAM (+) CD45 (–) CTCs were recovered by robotic micromanipulation for whole
genome amplification using multiple displacement amplification.
Mutation concordance
between CTCs and primary
or metastatic tumor tissue:
86%
- Experimental approach.
- High cost.
- Loss of concordance between
CTCs mutation and
primary/metastatic tumor
tissues.
ADNAtest (48). Is a device able to isolate MUC1-negative and EpCAM positive CTCs. After CTCs
isolation, cells are lysed and RNA is extracted for downstream analyses with RT-PCR.
Of note this device adopts primers against EGFR, PSA and PSMA making a sample
positive if one of these genes are expressed.
CTCs detection rate: 62% - Experimental approach
- High cost
- Few data about the application
of this approach in localized/
non metastatic prostate
cancer.
Moreover, another possible issue which could partially explain
the failure of this approach in clinical practice is the low detection
rate of CTCs in non metastatic patients which ranges only from
5 to 27% (54). To avoid this problem, Kuske et al combined three
different methods for the detection of CTCs before and after
prostatectomy in non metastatic patients with PC, CellSearch
system assay, CellCollector (a system capturing EpCAM-positive
CTCs by an antibody-coated needle introduced in arm vein) and
EPISPOT (a system able to enrich CTCs by negative depletion
of leukocytes and detects circulating prostate cancer cells thanks
to their active secretion of PSA) (45). CTCs were detected in 37,
54.9 and 58.7% of patients using CellSearch, CellCollector, and
EPISPOT, respectively. The cumulative positivity rate of the three
CTC assay was 81.3% and despite it is not a validated approach, it
represents an attractive early method able to estimate the risk of
tumor recurrence or persistence after surgery.
A combined analysis of COU-AA-301 and IMMC-38 trials
showed that an increase of 30% in CTCs count from baseline
was independently associated to worst OS in patients treated with
abiraterone and chemotherapy (53). To sustain the correlation
between CTCs count changes and survival, another analysis
performed on 119 patients with CRPC treated at the Royal
Marsden Hospital suggested that a decrease of 30% in CTC
counts from baseline was associated to improved survival (55).
The only CTCs enumeration resulted in an independent
prognostic factor with an unclear role in terms of early diagnosis
of disease recurrence/persistence after surgery as well as a
predictive response factor. Another interesting approach consists
in a characterization of CTCs resulting in a genetic assessment
and in a detection of target altered pathways.
AR protein has been extensively investigated in prostate
cancer CTCs. Through a FISH based assay AR gene amplification
detection in CTCs was possible in 40% of cases, a percentage
comparable to the AR amplification described in bone metastases
biopsy analyses (47). Further investigations demonstrated that
patients with higher cytoplasm expression of AR resulting in a
reduction of nuclear translocation was significantly associated
to better response to docetaxel (56). By a microfluidic capture
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of CTCs Miyamoto et al. evaluated dynamic changes in CTCs
AR expression. In particular, considering the expression of
PSA (up-regulated by AR) and PSMA (down regulated by AR)
they classified CTCs in AR on, AR mixed and AR positive
according to the expression of PSA (+ in AR on and mixed) and
PSMA (+ in AR off and mixed). Moreover, Authors identified
that AR status changed from “on” to “off” during ADT while
patients treated with abiraterone acetate with an increase of
AR-on CTCs or baseline level of AR-mixed more than 10%
were significantly associated to worse overall survival (46).
The technology developed by Myamoto et al was also adopted
for the detection of anti-androgen resistance mechanisms in
CTCs demonstrating higher activation of Wnt signaling and
considerable heterogeneity in signaling pathways, expression of
AR gene mutations and splicing variants (57).
Due to the important role of AR-V7 in mCRPC (35), several
studies have focused on the detection of this splice variants
on CTCs. An EpCAM assay demonstrated that CTCs-ARV7+
detection was associated to resistance to enzalutamide and
abiraterone but no to docetaxel and cabazitaxel and that the
detection of these CTCs was independently associated to worse
clinical outcome compared to patients with CTCs-ARV7- cells
(58–60). Other studies modified the CTCs and ARV7 detection
method in order to evaluate the AR-V7 cellular localization (61)
and the presence of other splice variants of AR (62). Particularly,
not only AR-V7 but also other slice variants of the AR protein
were significantly associated to worse progression free survival.
Moreover 6 of 17 poor responders to treatment were AR-V7
negative, but carried other AR perturbations (62).
About other pathways detected in CTCs, the PTEN loss
assessed by FISH and Epic Sciences test (an assay which adopted
a fibreoptic array scanning techniques for the detection of DAPI,
CD45, cytokeratins stained cells) has been associated to worse
clinical outcomes (63, 64) while the detection of TMPRSS2-ERG
fusion gene performed by microfluidic device and by the use of
a RT-PCR analysis failed to show a predictive response value to
abiraterone acetate in mCRPC patients (47).
Next Generation Sequencing (NGS) involves a series of
different techniques able to perform a whole genome sequencing
of tumor cells. The possibility to obtain a complete genomic
assessment from CTCs appears a novel and promising approach
investigated in different studies.
In 2014, Lohr et al evaluated a method able to perform a
CTCs isolation, enrichment (throuEp-CAM expressing CTCs),
genomic amplification and sequencing in metastatic PC (65).
They demonstrated that a complete mapping of the standard
exome was possible in CTCs. NGS analysis of CTCs and tumor
sample of a single patient with advanced prostate cancer showed
a concordance of 86% from the mutations isolated in CTCs and
genomic anomalies identified in primary or metastatic tumors
(66). Despite NGS performed to CTCs represents an attractive
approach, to date no validated or prospective studies have been
carried out and so this method is still under investigation.
Another interesting issue is the detection of whole blood
RNA, without enriching for CTC. In 2012, Ross et al assessed a
whole blood RNA transcript based model as prognostic factor
in patients with PC. After the analysis of blood collected from
62 men with mCRPC, they identified a six gene model (genes
considered were: ABL2, SEMA4D, ITGAL, C1QA, TIMP1,
CDKN1A which are genes involved mainly in immunity
regulation) able to divide patients in two risk groups with
different mOS (67). In the same year, Olmos et al carried
out a validation study of a nine-gene signature as prognostic
factor (68). Design of the study consisted in a derivation
set in which patients with mCRPC and patients in Active
Surveillance were used as case and control groups respectively.
After genomic assessment 94 patients were divided in four
distinct prognostic groups. Thus nine altered genes HMBS,
TMCC2, SLC4A1, STOM, GABARAPL2, RIOK3, TERF2IP,
TFDP1) isolated in prognostic groups with worst survival
(composed of only mCRPC patients) were validated in a
validation set of patients with mCRPC. More recently, an
assessment of 5 key genes (KLK3, KLK2, HOXB13, GRHL2,
FOXA1) obtained after reverse transcription polymerase chain
reaction (RT-PCR) demonstrated to be a reliable prognostic
marker compared to CellSearch system count (48). Isolation of
two or more of the selected genes were possible in 53% (51
/97) patients with mCRPC. AdnaTest is a technique adopted for
CTCs enrichment and consists of a device able to isolate MUC1-
negative and EpCAM positive CTCs. After CTCs isolation, cells
are lysed and RNA is extracted for downstream analyses with
RT-PCR. Of note this device adopts primers against EGFR,
PSA, and PSMA making a sample positive if one of these genes
are expressed. Sensitivity of KLK2, KLK3, HOXB13, GRHL2,
and FOXA1 genes detection by this method is similar to
DDPCR (direct detection PCR) and both of these techniques
showed a higher sensitivity compared to CellSearch system
(69).
Concerning the several devices utilized for CTCs detection,
enrichment and evaluation, only CellSearch has been approved
from FDA. However, despite a large range of potential
applications (such as diagnosis, evaluation of treatment response,
early detection of tumor relapse, and progression) CTCs
detection by CellSearch is not commonly adopted in clinical
practice. This mainly due to a low sensitivity of the method
as well as a conflicting relationship between CTCs and
treatment response evaluation. Several other approaches are
under investigation. It is likely that CTCs evaluation will be an
important factor able to improve our decisions in clinical practice
(48, 69).
CIRCULATING DNA IN PROSTATE
CANCER
The evidence that cell-free DNA could be detected in peripheral
blood is a well known issue, and its application in clinical
practice has been investigated only in last years. Regarding
cancer patients, the unique composition of tumors’ ctDNA
presenting several genomic mutations (especially single base-pair
substitution) which are not detectable in ctDNA originating from
normal cells make tumor ctDNA an ideal markers of the disease.
Moreover, the possible correlation between mutations detected
on ctDNA and genomic mutations of primary or metastatic
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tumors make cDNA a unique markers able to provide key
information by a no-invasive approach.
Regarding PC, ctDNA could be detected in peripheral blood
and detection of known driver aberrations can be obtained in
more than 97% of cases. Moreover, changings in ctDNA genomic
mutations could be detected by repeated analyses of ctDNA with
high grade of concordance with genomic assessment of primary
tumors or metastases (70, 71).
The quantitative assessment of ctDNA has been related
to prognosis of patients with PC in different studies (72,
73). In particular, Romanel A et al exanimated AR status of
mCRPC patients starting abiraterone acetate. They detected a
45% of patients (tot number 97) with AR point mutations
(T878A/L702H) before the first administration of abiraterone
who showed a significant worse overall survival (73). Similarly,
other studies confirmed the prognostic role of AR genomic
alterations as prognostic markers raising the acquisition of
ctDNA examination as a possible to monitor response to
hormonal agents and to achieve an early diagnosis of progressive
disease (74–77).
As known, mutation in DNA repair genes is acquiring an
increasing interest in PC due to the association by these mutation
and more aggressive tumor features and to the possible benefit
derived from a PARP targeted treatment. Mutations in repair
genes are common in prostate cancer. In a DNA assessment of
692 men with metastatic PC a total of 84 germiline DNA repair
gene mutations (BRCA2, ATM, CHEK2, BRCA1, RAD51D, and
PALB2) were found in 82 men (78). This study demonstrated
that incidence of germline mutations of DNA-repair gene were
common (as detected in 11.8% of all patients) in metastatic
patients regardless to age and family history of prostate cancer.
PARP inhibition is one of the important strategy currently
under investigation in patients withmetastatic prostate cancer. In
a phase II trial 50 mCRPC patients received the PARP inhibitor
Olaparib (41). 17 (33%) patients showed an objective response
while NGS sequencing showed that 16 patients presented
homozygous delections, deleterious mutations, or both in DNA
repair genes (BRCA1/2, ATM, Fanconi’s anemia genes and
CHECK2). A subsequent analysis of tumors DNA highlighted
that patients with an overall reduction of 50% or more of
ctDNA were associatied with better OS and PFS (79). In ASCO
2018, Clarke et al presented the results of a phase II study
comparing the administration of Abiraterone with Olaparib or
placebo in 171 patients with mCRPC (80). This trial met its
primary endopoint showing a better radiological PFS in patients
receiving olaparib. Of note Authors researched homologous
recombination repair mutations by a NGS approach in tumor
samples and plasma. Sequencing was possible on 91 of 136
patients and positive results (defined as discovery mutated
patients) was obtained in 13 patients. By germline analysis and
tumor sample analyses detection of homologous recombination
repair mutations were identified in 3 patients (38 tumor samples
analyzed of 68 total samples) and 7 patients (by a germline
analysis of 102 patients). Results of this study raising the dosage
and analyses of cDNA as possible approach for the detection of
keys DNA-repair gene mutations. Other larger prospective trials
are needed to explore the role of ctDNA in this setting.
Another promising target gene is represented by PTEN loss
which has show to be a predictive biomarker of response to
treatments targeting PI3K/AKT pathway. Hyper-activation of
the PI3K/Akt/mTOR resulting from PTEN loss is related to
decreased AR transcription output and stability and vice versa.
The addiction of ipatasertib (an Akt inhibitor) to abiraterone
acetate increased radiological PFS of patients with mCRPC and
PTEN loss previously treated with docetaxel based therapy and
progressed during at last one previous hormonal therapy (81).
Extracellular vesicles are membrane-enclosed structures that
are released from all cells in the body. These vesicles contain
several substances such as proteins, lipids, RNA, and DNA
and are considered a very promising tumor-related biomarkers.
Recently, it has been demonstrated that large extracellular
vesicles isolated from plasma of patients with prostate cancer
cells are an important source of chromosomal DNA which
reflects faithfully genetic aberration of the cell of origin, including
copy number variations of genes frequently altered in metastatic
prostate cancer (such as MYC and PTEN) (82). The study of
extracellular vesicles represents a novel and promising approach
for biomarkers development in prostate cancer however further
studies are needed to explore the effective value of this method.
CONCLUSION
The surprising potential of CTCs or tumors’ ctDNA detection,
characterization and genomic assessment have start a revolution
which probably will give important results in next years.
Despite to date application of these techniques are few probably
that better knowledge of genomic anomalies of PC and their
correlation with the clinical course of the disease as well as
their potential relationship with specific targeted treatments will
increase the attention on this issue.
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